Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
This article is being published in Kidney International Reports and reprinted concurrently in several journals. The articles cover identical concepts and wording but vary in minor stylistic and spelling changes, detail, and length of manuscript, in keeping with each journal’s style. Any of these versions may be used in citing this article. Excerpts are adapted with permission of KDIGO and the International Society of Nephrology.
TRI acknowledges the co-publication in AJKD, AJN, CRM, CKJ, CEN, CN, CONH, DRCP, JN, JON, JORC, JRN, KD, KM, KRCP, NEP, NDT, PN, PDI, RN, SN, and Transplantation.
Conflict of interest
ASL declared having received research support from AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases, and National Kidney Foundation. K-UE declared having received consultancy fees from Akebia, Bayer, and Genzyme; speaker honoraria from Bayer and Vifor; and research support from Amgen, AstraZeneca, Bayer, Fresenius Medical Care, and Genzyme. NMD declared having equity ownership/stock options from Eli Lilly & Co. MJ declared having received consultancy fees from Astellas, AstraZeneca, GSK, MSD, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Abbvie, Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma; travel support from Amgen; and research support from Alexion, Amgen, Janssen-Cilag, Otsuka, and Roche. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. All the other authors declared no competing interests.
